[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Jung CK, Park JS, Lee EJ, Kim SH, Kwon HC, Kim JS, Roh MS, Yoon SK, Kim KH, Han JY, Kim HJ: Autoimmune hemolytic anemia in a patient with primary ovarian non-Hodgkin's lymphoma. J Korean Med Sci; 2004 Apr;19(2):294-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune hemolytic anemia in a patient with primary ovarian non-Hodgkin's lymphoma.
  • The primary ovarian lymphoma is a rare disease with poor prognosis.
  • The incidence of autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma is estimated at 3%.
  • However, a substantial portion of the previously reported cases of ovarian lymphoma actually represented ovarian involvement by more diffuse lymphomatous process.
  • If stringent criteria are used for case selection, true primary ovarian lymphoma usually carries a favorable prognosis.
  • We present a primary malignant lymphoma of ovary accompanied by autoimmune hemolytic anemia in a 29-yr-old patient.
  • One year following surgery and chemotherapy, the patient is alive and disease free.
  • [MeSH-major] Anemia, Hemolytic / immunology. Lymphoma, Non-Hodgkin / complications. Ovarian Neoplasms / complications
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Autoimmune Diseases / immunology. Combined Modality Therapy. Female. Humans. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1974 Aug;34(2):397-407 [4853080.001]
  • [Cites] Am J Obstet Gynecol. 1982 Aug 15;143(8):870-5 [7102762.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Blood. 1990 Aug 1;76(3):562-9 [2378986.001]
  • [Cites] Gynecol Oncol. 1992 Apr;45(1):69-75 [1601335.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:152-4 [1434818.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1571-7 [11205465.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jun;118(6):647-50 [8204013.001]
  • [Cites] Leuk Lymphoma. 1995 Jul;18(3-4):311-6 [8535198.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):446-50 [9062148.001]
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):137-40 [9698492.001]
  • [Cites] Am J Obstet Gynecol. 1963 Apr 1;85:912-8 [14001792.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):154-70 [8422111.001]
  • (PMID = 15082907.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2822315
  •  go-up   go-down


2. Elharroudi T, Ismaili N, Errihani H, Jalil A: Primary lymphoma of the ovary. J Cancer Res Ther; 2008 Oct-Dec;4(4):195-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the ovary.
  • Involvement of the ovary by malignant lymphoma is a well-known late manifestation of disseminated nodal disease.
  • Primary ovarian lymphoma is rare.
  • We report a case of primary ovarian non-Hodgkin's lymphoma with bilateral involvement which was managed by surgery and chemotherapy.
  • Computed tomography revealed an abdominal tumor measuring 20 cm in diameter, without enlarged lymph nodes.
  • The diagnosis of malignant lymphoma was established after bilateral adnexectomy and histological study of the excised tissue.
  • The tumor was classified as a diffuse large B-cell lymphoma.
  • The patient has been advised 8 cycles of standard CHOP regimen and is presently on treatment.
  • According to previous reports the treatment principles and prognosis of primary ovarian lymphoma is the same as that of other nodal lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antigens, Neoplasm / chemistry. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Positron-Emission Tomography / methods. Prednisolone / therapeutic use. Prognosis. Tomography, X-Ray Computed / methods. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052394.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


3. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma.
  • Bilateral ovarian enlargement may reflect benign or malignant processes of the ovary.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • The patient responded well to chemotherapy with significant shrinkage of the tumor, and reappearance of normal findings on ovarian sonography.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • RESULTS: Thirty-five patients (47%) initially were misdiagnosed, and the disease was most often malignant lymphoma.
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


5. Yamada T, Iwao N, Kasamatsu H, Mori H: A case of malignant lymphoma of the ovary manifesting like an advanced ovarian cancer. Gynecol Oncol; 2003 Jul;90(1):215-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of malignant lymphoma of the ovary manifesting like an advanced ovarian cancer.
  • BACKGROUND: In recent years, true primary ovarian lymphoma has been considered to carry a favorable prognosis, although most studies of supposedly primary ovarian lymphoma have reported a poor outcome.
  • The diagnosis of malignant lymphoma was established from the biopsy specimen after exploratory laparotomy.
  • Six years following chemotherapy, the patient is alive and disease free without additional surgery.
  • CONCLUSION: The prognosis of ovarian lymphoma was evaluated according to clinical stage, modality of onset, histologic type, and phenotype.
  • It remains controversial whether this case can be considered truly primary ovarian lymphoma and not merely a localized initial manifestation of a generalized disease.
  • But if this case of advanced ovarian lymphoma were not primary, it could still be managed successfully with chemotherapy appropriate for the specific histology.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12821369.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Bergom C, Paddock C, Gao C, Holyst T, Newman DK, Newman PJ: An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling. J Cell Sci; 2008 Apr 15;121(Pt 8):1235-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling.
  • Using a novel rabbit polyclonal antibody that specifically recognizes Delta15 PECAM-1, we found that the Delta15 PECAM-1 isoform was expressed in human tissues, including brain, testes and ovary.
  • This isoform was also expressed on the cell surface of human platelets, human umbilical vein endothelial cells (HUVECs) and the Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines.
  • Delta15 PECAM-1 was unable, however, to protect against apoptosis induced by overexpression of Bax or treatment with the chemotherapy agent etoposide.
  • These studies suggest a novel role for the PECAM-1 C-terminus in cytoprotective signaling and highlight a need for further characterization of expression of PECAM-1 isoforms in normal and malignant tissues.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Feb 1;162(3):1376-83 [9973392.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):3022-30 [10072554.001]
  • [Cites] J Cell Sci. 1999 Jun;112 ( Pt 12):1989-97 [10343075.001]
  • [Cites] J Immunol. 1999 Jul 15;163(2):682-8 [10395658.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1319-29 [10438720.001]
  • [Cites] J Neurooncol. 1999 May;43(1):19-25 [10448867.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6403-8 [15528380.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H159-64 [15319204.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):185-96 [15632011.001]
  • [Cites] J Biol Chem. 1992 Mar 15;267(8):5243-9 [1544907.001]
  • [Cites] J Exp Med. 1992 Jul 1;176(1):245-53 [1377224.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):449-60 [8340753.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2649-63 [7693043.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1580-2 [8248808.001]
  • [Cites] J Exp Med. 1994 Mar 1;179(3):1059-64 [8113674.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2055-9 [8174104.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17183-91 [8006026.001]
  • [Cites] Ann N Y Acad Sci. 1994 Apr 18;714:165-74 [8017765.001]
  • [Cites] Development. 1994 Sep;120(9):2539-53 [7956830.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4673-83 [7525710.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4028-37 [7994021.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):299-307 [7995949.001]
  • [Cites] Trends Cardiovasc Med. 2002 Jul;12(5):213-9 [12161075.001]
  • [Cites] J Cell Biochem. 2002;87(4):424-38 [12397602.001]
  • [Cites] J Exp Med. 2002 Nov 4;196(9):1201-11 [12417630.001]
  • [Cites] Blood. 2003 Jan 1;101(1):186-93 [12393747.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3169-77 [15632208.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):559-70 [15786495.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4865-77 [16219692.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R57-65 [16166207.001]
  • [Cites] Blood. 2006 Jan 15;107(2):535-41 [16166583.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):480-2 [16594742.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1699-707 [17106245.001]
  • [Cites] Blood. 2007 May 15;109(10):4237-44 [17234740.001]
  • [Cites] Blood. 2007 Aug 1;110(3):851-9 [17412889.001]
  • [Cites] Cell Adhes Commun. 1995 Feb;3(1):45-66 [7538415.001]
  • [Cites] J Leukoc Biol. 1999 Nov;66(5):698-704 [10577496.001]
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 8):1459-69 [10725228.001]
  • [Cites] Mol Biol Cell. 2000 Aug;11(8):2793-802 [10930470.001]
  • [Cites] Tissue Antigens. 2000 Aug;56(2):105-16 [11019910.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):65-73 [11149921.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):457-60 [11233910.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1727-32 [11238114.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3098-106 [11207261.001]
  • [Cites] FASEB J. 2001 May;15(7):1257-60 [11344106.001]
  • [Cites] Dev Biol. 2001 Jun 15;234(2):317-29 [11397002.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1456-63 [11520795.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90 [11940533.001]
  • [Cites] Blood. 2002 Jul 1;100(1):184-93 [12070026.001]
  • [Cites] J Exp Med. 1989 Aug 1;170(2):399-414 [2666561.001]
  • [Cites] Science. 1990 Mar 9;247(4947):1219-22 [1690453.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):1227-37 [2182647.001]
  • [Cites] J Immunol. 1992 Jan 15;148(2):388-96 [1345920.001]
  • [Cites] Thromb Haemost. 1991 Oct 1;66(4):494-9 [1796401.001]
  • [Cites] Thromb Haemost. 1991 Dec 2;66(6):700-7 [1796415.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H1008-17 [12433657.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2816-25 [12468430.001]
  • [Cites] FEBS Lett. 2003 Apr 10;540(1-3):7-14 [12681475.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):953-64 [12689916.001]
  • [Cites] Blood. 2003 Jul 1;102(1):169-79 [12649141.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3658-64 [12893757.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2336-44 [12893640.001]
  • [Cites] Mol Vis. 2004 Feb 17;10:103-11 [14978479.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23672-80 [7559536.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1337-43 [7595204.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1515-24 [8568255.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11090-8 [8626652.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18561-70 [8702505.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):6986-93 [9054388.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2139-51 [9151786.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2152-64 [9151787.001]
  • [Cites] FEBS Lett. 1997 May 26;408(3):331-6 [9188788.001]
  • [Cites] Mol Biol Cell. 1997 Jul;8(7):1329-41 [9243511.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20555-63 [9252369.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24868-75 [9312087.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31086-91 [9388260.001]
  • [Cites] J Clin Invest. 1998 Jan 1;101(1):212-22 [9421484.001]
  • [Cites] Blood. 1998 Jan 15;91(2):500-7 [9427703.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):5-9 [9884328.001]
  • [Cites] Dev Dyn. 1999 Jan;214(1):44-54 [9915575.001]
  • (PMID = 18388311.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL040926-20; United States / NHLBI NIH HHS / HL / R01 HL040926; United States / NHLBI NIH HHS / HL / HL-40926; United States / NHLBI NIH HHS / HL / R01 HL040926-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS71027; NLM/ PMC2567807
  •  go-up   go-down


7. Virtanen A, Pukkala E, Auvinen A: Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer; 2006 Feb 15;118(4):1017-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients.
  • Radiotherapy is commonly used for treatment of malignant disease.
  • As a consequence of radiotherapy, an increased risk of developing a second malignant neoplasm has been shown.
  • The aim of this study was to examine the risk of developing a bone or soft tissue sarcoma after radiotherapy for a first primary cancer.
  • The study population included all the patients with primary cancers of breast, cervix uteri, corpus uteri, lung, ovary, prostate, rectum and lymphoma diagnosed during 1953-2000 and identified from the Finnish Cancer Registry.
  • Compared to the national incidence rates, after 10 years of follow-up sarcoma risk was increased among patients who had received neither radiotherapy nor chemotherapy (standardised incidence ratio (SIR) 2.0, 95% CI 1.3-3.0), radiotherapy without chemotherapy (SIR 3.2, 95% CI 2.3-4.3), chemotherapy without radiotherapy (SIR 4.9, 95% CI 1.0-14.4), as well as combined radiotherapy and chemotherapy (SIR 3.4, 95% CI 0.4-12.5).


8. Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J: Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood; 2010 Oct 21;116(16):2908-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe.
  • Ovarian tissue cryopreservation is currently proposed to young cancer patients to preserve their fertility before radiochemotherapy.
  • The potential risk is that the tissue might harbor malignant cells that could induce disease recurrence.
  • We therefore decided to evaluate the presence of leukemic cells in cryopreserved ovarian tissue from 18 leukemic patients: 6 with chronic myeloid leukemia (CML) and 12 with acute lymphoblastic leukemia (ALL).
  • Histology did not identify any malignant cells in the ovarian tissue.
  • By quantitative RT-PCR, 2 of 6 CML patients were positive for BCR-ABL in their ovarian tissue.
  • Among the 12 ALL patients, 7 of the 10 with available molecular markers showed positive leukemic markers in their ovarian tissue (translocations or rearrangement genes).
  • Four mice grafted with ovarian tissue from ALL patients developed intraperitoneal leukemic masses.
  • In conclusion, this study demonstrates, by quantitative RT-PCR, ovarian contamination by malignant cells in acute as well as chronic leukemia, whereas histology fails to do so.
  • Moreover, chemotherapy before ovarian cryopreservation does not exclude malignant contamination.
  • Finally, reimplantation of cryopreserved ovarian tissue from ALL and CML patients puts them at risk of disease recurrence.
  • [MeSH-major] Cryopreservation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Ovary / pathology. Ovary / transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Animals. Child. Child, Preschool. Female. Humans. Mice. Mice, SCID. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous / pathology. Young Adult


9. Mansouri H, Sifat H, Gaye M, Hassouni K, Mansouri A, El Gueddari B: Primary malignant lymphoma of the ovary: an unusual presentation of a rare disease. Eur J Gynaecol Oncol; 2000;21(6):616-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the ovary: an unusual presentation of a rare disease.
  • Because the outcome of patients with primary ovarian non-Hodgkin's lymphoma (NHL) is controversial, we present the incidental finding of a primary malignant lymphoma of the ovary in a 50-year-old patient.
  • Three and a half years following ablative surgery and adjuvant chemotherapy, the patient is alive and disease free.
  • Ovarian lymphoma is a disease of reportedly poor prognosis.
  • However, many previously reported cases of ovarian lymphoma actually represented ovarian involvement by a more diffuse lymphomatous process.
  • If stringent criteria are used for case selection, true primary ovarian lymphoma is a very rare disease and usually carries a favorable prognosis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large-Cell, Immunoblastic / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214624.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Blumenfeld Z: Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol; 2007 Mar;32(1):23-34
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
  • Decreased secretion of pituitary gonadotropins, by decreasing gonadal function, may possibly protect against the sterilizing effects of chemotherapy.
  • The only prospective randomized study performed to date found that gonadotropin releasing hormone agonistic analogue (GnRH-a) protected the ovary against cyclophosphamide-induced damage in Rhesus monkeys by significantly decreasing the number of follicles lost during the chemotherapeutic insult.
  • We have administered a monthly depot i.m. injection of GnRH-a to more than 125 young patients exposed to gonadotoxic chemotherapy for malignant or nonmalignant diseases, after informed consent, starting before chemotherapy for up to 6 months, in parallel and until the end of chemotherapeutic treatment.
  • Less than 7% developed irreversible hypergonadotropic amenorrhea.
  • The remainder (>93%) resumed cyclic ovarian function, of which 32 patients spontaneously conceived 46 times.
  • These patients were compared to a control group of over 125 patients of comparable age (15-40 years), who were similarly treated with chemotherapy but without the GnRH-a adjuvant.
  • The 2 groups were similar in age, diagnosis, and the ratio of HD to non-Hodgkin lymphoma patients.
  • The 2 groups also received similar doses of radiotherapy exposure and the proportion of radio-plus chemotherapy-treated patients was similar.
  • Possible explanations for the beneficial effect of the GnRH-a on minimizing the gonadotoxic effect of chemotherapy are discussed.
  • [MeSH-minor] Adolescent. Adult. Animals. Autoimmune Diseases / drug therapy. Azoospermia / chemically induced. Azoospermia / etiology. Clinical Trials as Topic. Cohort Studies. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Embryo Transfer. Female. Fertilization in Vitro. Germ Cells / drug effects. Germ Cells / radiation effects. Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / radiotherapy. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Macaca mulatta. Male. Mice. Ovary / physiopathology. Pregnancy. Pregnancy Outcome. Primary Ovarian Insufficiency / chemically induced. Primary Ovarian Insufficiency / prevention & control. Primary Ovarian Insufficiency / radiotherapy. Radiotherapy / adverse effects. Triptorelin Pamoate / administration & dosage. Triptorelin Pamoate / pharmacology. Triptorelin Pamoate / therapeutic use

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353864.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 77
  •  go-up   go-down


11. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M: Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus; 2000;9(6):401-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
  • BACKGROUND: Premature ovarian failure (POF) is a common long-term consequence of chemotherapy.
  • Whereas the cytotoxic-induced damage is reversible in other tissues of rapidly dividing cells such as bone marrow, gastrointestinal tract and thymus, it appears to be progressive and irreversible in the ovary, where the number of germ cells is limited, fixed since the fetal life, and cannot be regenerated.
  • In patients with lupus nephritis, premature ovarian failure (POF) was reported in half of all treated women after cyclophosphamide pulse therapy, affecting 100% of those older than 30 y, about 50% of the patients between the ages of 20-30y and only 13% of the patients younger than 20y of age.
  • Following our preliminary encouraging experience in women with lymphoma, whereby the temporary induction of a prepubertal hormonal milieu, during chemotherapy, has significantly decreased the risk of POF, we have administered a monthly injection of gonadotropin-releasing hormone agonistic analogue (GnRH-a) to eight young women in parallel to alkylating agent chemotherapy.
  • MATERIALS AND METHODS: A monthly intramuscular depot injection of 3.75 mg D-TRP6-GnRH-a (Decapeptyl C.R.) was administered after informed consent to eight women with autoimmune, severe connective tissue diseases (seven SLE patients and one woman with nephrotic syndrome) in parallel to chemotherapy, for up to six months.
  • The concentrations of FSH, LH, progesterone, and 17-beta-estradiol (E2) were measured before, during and after the GnRH-a/chemotherapy treatment.
  • A transvaginal (or transabdominal) sonography (TVS) was performed on each patient before and after treatment.
  • These eight treated patients (study group) were compared to a group of nine women similarly treated by cyclophosphamide pulses (CPT) or chlorambucil for SLE/connective tissue disease but were not referred for the GnRH-a adjuvant treatment.
  • RESULTS: Whereas none of the eight women receiving GnRH-a in parallel to alkylating agent chemotherapy (cyclophosphamide (7) or chlorambucil (1)) suffered POF and hypergonadotropic amenorrhea, five of the nine ( > 50%) patients treated by alkylating agents (cyclophosphamide (8) or chlorambucil (1)) experienced POF.
  • Whereas two of these five women were 35 y old, the other three were < or = 23 y old at the time of the chemotherapeutic insult.
  • CONCLUSIONS: Our present results, extrapolating this encouraging experience from hematological malignant diseases to severe connective tissue diseases, such as SLE associated nephropathy or others, suggests that the beneficial effect of GnRH-a co-treatment may be exploited towards preservation of future fertility and ovarian function in every young woman of reproductive age, exposed to alkylating agents, such as cyclophosphamide and chlorambucil.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Cyclophosphamide / adverse effects. Fertility Agents, Female / administration & dosage. Gonadotropin-Releasing Hormone / administration & dosage. Lupus Erythematosus, Systemic / drug therapy. Primary Ovarian Insufficiency / prevention & control

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10981642.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antirheumatic Agents; 0 / Fertility Agents, Female; 33515-09-2 / Gonadotropin-Releasing Hormone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Blumenfeld Z: Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol; 2002 Feb 22;187(1-2):93-105
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
  • BACKGROUND: Following the improved long term survival in young women with lymphoma and leukemia undergoing chemotherapy, the preservation of future fertility has been the focus of recent interest.
  • Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryopreserved ovary has been raised, following experimental animal observations.
  • Therefore, until these innovative endeavors prove successful, and in parallel to them we attempted to minimize the gonadotoxic effect of chemotherapy by the co-treatment with a GnRH agonistic analogue to induce a temporary prepubertal milieu.
  • The immunoreactive inhibin-A and -B in these patients, before, during, and following the gonadotoxic chemotherapy were measured.
  • METHODS: A prospective clinical protocol was undertaken in 55 women with lymphoma, aged 15-40 years, ten with leukemia and eight undergoing chemotherapeutic treatments for non malignant diseases such as systemic lupus erythematosus (SLE) or other autoimmune diseases.
  • A monthly injection of depot D-TRP6-GnRH-a was administered from before starting the chemotherapy until its conclusion, up to a maximum of 6 months.
  • Hormonal profile (FSH, LH, E2, T, P4, IGF-1, IGF-BP3, and PRL) was taken before starting the GnRH-a/chemotherapy co-treatment, and monthly thereafter, until resuming spontaneous ovulation.
  • This group was compared with a control group of 55 women who have been treated with similar chemotherapy.
  • RESULTS: Whereas, all but three (40- and 36-year-old) of the surviving patients with GnRH-a/chemotherapy co-treatment group resumed spontaneous ovulation and menses within 12 months, less than half of the patients in the control group (chemotherapy without GnRH-a co-treatment) resumed ovarian function and regular cyclic activity (P<0.05).
  • Inhibin-A and -B decreased during the GnRH-a/chemotherapy co-treatment but increased to normal levels in patients who resumed regular ovarian cyclicity, and/or spontaneously conceived, as compared with low levels in those who developed POF.
  • The GnRH-a co-treatment should be considered in every woman in the reproductive age receiving chemotherapy, in addition to ART, and to the investigational attempts of ovarian cryopreservation for future in-vitro maturation, autotransplantation, or xenotransplantation.
  • [MeSH-minor] Biomarkers / blood. Female. Humans. Inhibins / blood. Ovary / drug effects. Ovary / physiology. Primary Ovarian Insufficiency / chemically induced. Primary Ovarian Insufficiency / diagnosis. Primary Ovarian Insufficiency / prevention & control

  • Genetic Alliance. consumer health - premature ovarian failure.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11988316.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / inhibin A; 0 / inhibin B; 57285-09-3 / Inhibins
  • [Number-of-references] 126
  •  go-up   go-down


13. Qiu LH, Wang HQ, Qian ZZ, Li W, Hou Y, Meng XR, Cui XZ, Hao XS: [Clinical characteristics and treatment analysis of primary breast lymphoma: 49 cases report]. Zhonghua Wai Ke Za Zhi; 2010 May 15;48(10):743-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment analysis of primary breast lymphoma: 49 cases report].
  • OBJECTIVE: To explore the morbidity, clinical characteristics, diagnosis, metastasis, treatment and prognosis of primary breast lymphoma (PBL).
  • METHODS: From January 1960 to August 2007, 49 cases with PBL were treated among 22811 cases of breast malignancy and 7337 cases of malignant lymphoma.
  • The clinical data of these 49 patients, included gender, age, pathologic type, breast X ray and B ultrasound examination results, involved lymph nodes and organs, treatment, survival time, were retrospectively analyzed.
  • Most of this group of PBL was non-Hodgkin lymphoma (48 cases).
  • Bone marrow (9 cases), lung (7 cases), meninges (4 cases) and ovary (4 cases) were frequently involved organs.
  • The prognosis in patients with radical mastectomy combined chemotherapy was much better than that in patient received super to local mastectomy plus chemotherapy or simple tumor resection plus chemotherapy (5-year survival rates were 21.4%, 0, 0, respectively).
  • CONCLUSIONS: PBL is a kind of rare lymphoma with incidence increasing sharply in the past few decades.
  • Diagnosis of PBL should adopt histological examination.
  • Radical mastectomy combined chemotherapy could bring better prognosis, but the prognosis is still poor.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646489.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Blumenfeld Z: Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig; 2001 Jan-Feb;8(1 Suppl Proceedings):S60-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: After improved long-term survival in young women with lymphoma and leukemia undergoing chemotherapy, preservation of future fertility has been the focus of recent interest.
  • Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryoperserved ovary has been raised after experimental animal observations.
  • Therefore, until these innovative endeavors prove successful, and in parallel with them, we attempted to minimize the gonadotoxic effect of chemotherapy by the cotreatment with a gonadotropin-releasing hormone (GnRH) agonistic analogue to induce a temporary prepubertal milieu.
  • Immunoreactive inhibin-A and -B in these patients before, during, and after gonadotoxic chemotherapy were measured.
  • METHODS: A prospective clinical protocol was undertaken in 44 women with lymphoma, aged 15--40 years, ten with leukemia and eight undergoing chemotherapeutic treatments for nonmalignant diseases such as systemic lupus erythematosus or other autoimmune diseases.
  • A monthly injection of depot D-TRP6-GnRH-a was administered from before the start of chemotherapy until its conclusion, up to a maximum of 6 months.
  • A hormonal profile was taken before starting the GnRH-a/chemotherapy cotreatment, and monthly thereafter until the women resumed spontaneous ovulation.
  • This group was compared with a control group of 55 women who had been treated with similar chemotherapy.
  • RESULTS: Whereas all but one (40-year-old) of the surviving patients with GnRH-a/chemotherapy cotreatment group resumed spontaneous ovulation and menses within 6 months, fewer than half of the patients in the control group (chemotherapy without GnRH-A cotreatment) resumed ovarian function and regular cyclic activity (P <.05).
  • Inhibin-A and -B decreased during GnRH-a/chemotherapy cotreatment but increased to normal levels in patients who resumed regular ovarian cyclicity and/or spontaneously conceived, compared with low levels in those who developed POF.
  • GnRH-a cotreatment should be considered for every woman of reproductive age who receives chemotherapy, in addition to assisted reproductive technology and the investigational attempts of ovarian cryopreservation for future in vitro maturation.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoimmune Diseases / drug therapy. Female. Humans. Inhibins / blood. Leukemia / drug therapy. Lymphoma / drug therapy. Pregnancy. Prospective Studies. Triptorelin Pamoate / administration & dosage

  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11223377.001).
  • [ISSN] 1071-5576
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 57285-09-3 / Inhibins; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


15. Nakamura S, Kato M, Ichimura K, Yatabe Y, Kagami Y, Suzuki R, Taji H, Kondo E, Asakura S, Kojima M, Murakami S, Yamao K, Tsuzuki T, Adachi GK, Miwa A, Yoshidai T: Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases. Int J Hematol; 2001 Jan;73(1):108-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases.
  • Malignant lymphoma of the female genital tract (FGT) is rare.
  • They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000.
  • Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification.
  • Four of 5 patients received laparotomy and chemotherapy.
  • Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up.
  • Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunophenotyping. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1988 Aug;90(2):156-62 [3293419.001]
  • [Cites] Am J Obstet Gynecol. 1982 Aug 15;143(8):870-5 [7102762.001]
  • [Cites] Obstet Gynecol. 1974 Nov;44(5):735-48 [4528975.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1198-205 [8635144.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):651-4 [10203609.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):567-78 [10609794.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):619-22 [10609801.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Pathol Int. 1997 Jan;47(1):38-53 [9051691.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1236-41 [9331298.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):284-96 [7532919.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):457-64 [1331609.001]
  • [Cites] Mod Pathol. 1999 Feb;12(2):109-15 [10071336.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] J Obstet Gynaecol Res. 1998 Jun;24(3):183-7 [9714988.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2255-60 [8161791.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):126-8 [3531726.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):128-30 [1967431.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Immunol Today. 2000 Apr;21(4):160-3 [10740235.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):719-25 [10800991.001]
  • [Cites] Ultrastruct Pathol. 1990 May-Jun;14(3):247-52 [2192488.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Obstet Gynecol. 1984 Sep;64(3 Suppl):93S-94S [6472755.001]
  • [Cites] Jpn J Clin Oncol. 1989 Jun;19(2):163-6 [2733170.001]
  • [Cites] Cancer. 1974 Aug;34(2):397-407 [4853080.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Apr;95(4):386-90 [3382612.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):1893-900 [9176382.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3785-91 [7524749.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:31-84 [13743408.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):154-70 [8422111.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1723-31 [9473239.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • [Cites] Immunol Today. 1991 Nov;12(11):415-9 [1786074.001]
  • [Cites] Hum Pathol. 1990 Oct;21(10):1041-50 [2210727.001]
  • [Cites] Hematol Oncol. 1990 Sep-Oct;8(5):295-9 [1701156.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2530-45 [6585265.001]
  • (PMID = 11372745.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


16. Potolog-Nahari C, Fishman A, Cohen I: Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females. Gynecol Endocrinol; 2007 May;23(5):290-4
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
  • Cytotoxic treatment can cause early loss of ovarian function associated with loss of fertility in younger women.
  • To investigate if co-treatment with a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist may be useful in preserving ovarian function and fertility in younger women during chemotherapy, we prospectively observed nine young patients receiving different chemotherapies for various malignant diseases and other severe medical conditions who also received simultaneous GnRH agonist and GnRH antagonist.
  • Eight (88.9%) patients regained normal basal hormonal profile within 3 - 6 months after the completion of chemotherapy.
  • Eight (88.9%) patients resumed spontaneous menses within 3 - 11 months following discontinuation of chemotherapy.
  • It seems that combined usage of GnRH agonist and GnRH antagonist during chemotherapy may be useful in preserving ovarian function and fertility in a group of young females receiving chemotherapy treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Goserelin / therapeutic use. Hormone Antagonists / therapeutic use. Infertility, Female / prevention & control
  • [MeSH-minor] Adolescent. Adult. Age Factors. Case-Control Studies. Drug Therapy, Combination. Female. Humans. Lymphoma / drug therapy. Ovary / drug effects. Prospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • Hazardous Substances Data Bank. CETRORELIX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Endocrinol. 2008 Feb;24(2):64-5; author reply 66 [18210327.001]
  • (PMID = 17558688.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hormone Antagonists; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone; OON1HFZ4BA / cetrorelix
  •  go-up   go-down


17. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E: Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol; 2002 Aug;25(4):371-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in oncology practice: relation to diseases and their therapies.
  • Anemia is common in patients with cancer and is a frequent complication of myelosuppressive chemotherapy.
  • In this study, we investigated the incidence and severity of chemotherapy-induced anemia caused by the most common chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults.
  • Five hundred fifty-two patients with histologically proven carcinoma originating from breast (n = 165), lung (n = 128), colon (n = 75), ovary (n = 84), and malignant lymphoma (n = 100) were included in this study.
  • Hemoglobin levels for each patient were measured with an automatic counter during both pretreatment and before each chemotherapy cycle during therapy.
  • Before chemotherapy, 44% of patients with breast carcinoma had anemia.
  • There was a 16% increase in the incidence of anemia after chemotherapy.
  • However, single-agent chemotherapy with newer generation caused more anemia when compared with the FAC regimen (p < 0.005).
  • Chemotherapy resulted in a significant decrease in hemoglobin levels when compared with pretreatment values in patients with lung cancer (p < 0.001).
  • During treatment, the increase in the incidence of grade II anemia was associated with a parallel decrease in the incidence of grade I anemia.
  • Seventy-one percent of patients with colon cancer had anemia before initiation of chemotherapy.
  • Chemotherapy resulted in a prominent increase in incidence of anemia, which increased to 91.5%.
  • Less than 10% of patients developed severe anemia.
  • Showing a high incidence of anemia (82%) at presentation, hemoglobin levels in patients with malignant lymphoma were unaltered with chemotherapy.
  • There was a higher incidence of anemia in patients with non-Hodgkin's lymphoma receiving the cyclophosphamide, epirubicin, vincristine, prednisone (CEOP) regimen in contrast to patients with Hodgkin's lymphoma treated with the doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) combination.
  • In this study, we have observed equivalent rates of treatment-related anemia when compared with previous data in patients with specific tumor types.
  • The mechanisms underlying the propensity for a higher risk of pretreatment anemia in patients with malignant disorders and its influence on the outcome has to be elucidated by further population-based and molecular studies.
  • [MeSH-major] Anemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Female. Humans. Incidence. Lung Neoplasms / drug therapy. Lymphoma / drug therapy. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151968.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM: Fertility after treatment for Hodgkin's disease. Ann Oncol; 2002;13 Suppl 1:138-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility after treatment for Hodgkin's disease.
  • Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryoperserved ovary has been raised following experimental animal observations.
  • Therefore, until these innovative endeavors prove successful, we have attempted to minimize the gonadotoxic effect of chemotherapy by the co-treatment with a gonadotropin-releasing hormone agonistic analog (GnRH-a) to induce a temporary prepubertal milieu.
  • The immunoreactive inhibin-A and -B in these patients was measured before, during and following the gonadotoxic chemotherapy.
  • METHODS: A prospective clinical protocol was undertaken in 60 women aged 15-40 years with lymphoma, 10 with leukemia and 10 undergoing chemotherapeutic treatments for non-malignant diseases such as systemic lupus erythematosus or other autoimmune diseases.
  • A monthly injection of depot D-TRP(6)-GnRH-a was administered from before starting the chemotherapy until its conclusion, up to a maximum of 6 months.
  • Hormonal profile [follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, T, P4, insulin-like growth factor (IGF)-1, IGF-BP3 and prolactin) was taken before starting the GnRH-a/chemotherapy co-treatment, and monthly thereafter until resumtion of spontaneous ovulation.
  • This group was compared with a control group of 60 women who have been treated with similar chemotherapy.
  • RESULTS: Whereas all but three (40, 36 and 34 year old) of the surviving patients within the GnRH-a/ chemotherapy co-treatment group resumed spontaneous ovulation and menses within 12 months, less than half of the patients in the 'control' group (chemotherapy without GnRH-a co-treatment) resumed ovarian function and regular cyclic activity (P <0.05).
  • Inhibin-A and -B decreased during the GnRH-a/ chemotherapy co-treatment but increased to normal levels in patients who resumed regular ovarian cyclicity, and/or spontaneously conceived, as compared with low levels in those who developed POF.
  • CONCLUSIONS: If these preliminary data are consisent in a larger group of patients, GnRH-a co-treatment should be considered in every woman of reproductive age receiving chemotherapy, in addition to assisted reproductive technologies and the investigation into ovarian cryopreservation for future in vitro maturation, autotransplantation or xenotransplantation.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Mar;14(3):499; author reply 499-500 [12598361.001]
  • (PMID = 12078896.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / inhibin A; 0 / inhibin B; 57285-09-3 / Inhibins; 57773-63-4 / Triptorelin Pamoate
  • [Number-of-references] 104
  •  go-up   go-down


19. Huser M, Crha I, Hudecek R, Ventruba P, Zakova J, Smardova L, Kral Z: Ovarian tissue cryopreservation--new opportunity to preserve fertility in female cancer patients. Eur J Gynaecol Oncol; 2007;28(4):249-55
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tissue cryopreservation--new opportunity to preserve fertility in female cancer patients.
  • INTRODUCTION: Malignant disease and the therapy are major factors that may result in complete loss of fertility.
  • A modern and potentially effective method of reproductive function protection is ovarian tissue cryopreservation.
  • Furthermore, the authors' own experience with this novel and interesting method of ovarian tissue protection is presented.
  • Ovarian tissue was obtained during laparoscopic surgery in five nuliparous women (aged 19-33) with a diagnosis of lymphoma before chemotherapy from 2004 to 2006.
  • After laboratory preparation, tissue was frozen by a slow cooling technique and stored in liquid nitrogen.
  • RESULTS: In total 75 women with malignant lymphoma before chemotherapy were referred to our center for consultation--68 chose ovarian inactivation by GnRH analogues during chemotherapy, two IVF cycles with embryo or oocyte cryopreservation and five ovarian tissue cryopreservation.
  • Totally 20 cryotubes with three pieces of tissue in each were cryopreserved.
  • CONCLUSIONS: Cryopreservation of ovarian tissue represents an effective alternative or addition to the cryopreservation of embryos or oocytes for women at risk of premature ovarian failure due to chemotherapy.
  • [MeSH-major] Cryopreservation / methods. Infertility, Female / prevention & control. Ovary / transplantation
  • [MeSH-minor] Adult. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Neoplasms / therapy. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713087.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 33
  •  go-up   go-down


20. Meirow D: Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol; 2000 Nov 27;169(1-2):123-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproduction post-chemotherapy in young cancer patients.
  • High-dose chemotherapy and radiotherapy has increased long-term survival of young patients with cancer.
  • With conventional chemotherapy, there is significant differences in ovarian failure rate according to patients age, disease for which patients are treated for, and the drugs used.
  • Bone marrow transplantation in cancer patients almost invariably induced ovarian failure, irrespective of patient age, treatment protocol or administration of hormonal treatment.
  • Moreover, normal reproductive parameters post-chemotherapy does not necessarily imply that the ovaries escaped damage; ovarian injury is not an all or none phenomenon--partial loss of primordial follicle reserve can result in premature menopause as a delayed reaction to treatment.
  • The direct mechanisms of chemotherapy induced ovarian failure are poorly understood.
  • An in vitro study has demonstrated that in the human ovary chemotherapy acts primarily on primordial follicles through induction of apoptotic changes in pregranulosa cells which lead to follicle loss.
  • Protecting fertility potential in females exposed to chemotherapy with IVF and embryo cryopreservation or cryopreservation of ovarian tissue is practiced.
  • Ovarian tissue cryopreservation: A recent study has demonstrated that laparoscopic ovarian biopsy performed with the round biopter is a safe and efficient method for collecting ovarian tissue for cryopreservation in cancer patients.
  • In order to avoid possible hazards of transferring malignant cells, genetic and immunohistochemical markers for detection of minimal residual cancer cells in ovarian tissue are currently used.
  • IVF: IVF and embryocryopreservation is currently used in infertile patients, however, several obstacles prevent it's wide implementation in cancer patients such as the need for male partner and the time needed for ovarian stimulation.
  • A highly important issue is the possible risk of performing IVF and embryo cryopreservation to preserve fertility in females already exposed to chemotherapy.
  • An animal study has raised serious concerns regarding the consequences of chemotherapy on future pregnancies.
  • High abortion and malformation rates related to the different stages of oocyte maturation at the time of exposure to chemotherapy were demonstrated.
  • These results should be taken into account when considering the use of IVF and embryo cryopreservation following chemotherapy treatment in cancer patients.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Bone Marrow Transplantation / adverse effects. Breast Neoplasms / complications. Breast Neoplasms / physiopathology. Breast Neoplasms / therapy. Cohort Studies. Cryopreservation / methods. Female. Fertilization in Vitro / methods. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / physiopathology. Leukemia, Myeloid, Acute / therapy. Lymphoma / complications. Lymphoma / physiopathology. Lymphoma / therapy. Ovary / cytology. Primary Ovarian Insufficiency / chemically induced. Primary Ovarian Insufficiency / etiology. Primary Ovarian Insufficiency / pathology. Retrospective Studies. Risk Factors. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11155944.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN: Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod; 2005 Dec;20(12):3539-46
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation.
  • BACKGROUND: The purpose of this study was to assess the ovarian function after treatment of a malignant disease in women who previously had cortical tissue from an entire ovary cryopreserved prior to chemotherapy, and to assess ovarian function after autotransplantation of cryopreserved ovarian tissue.
  • All were treated with chemotherapeutic drugs with an estimated high risk of inducing ovarian failure.
  • Three patients with premature ovarian failure had ovarian tissue autotransplanted orthotopically and heterotopically.
  • Ovarian function was assessed by ultrasonography of the remaining ovary and hormone measurements.
  • All three patients with autotransplanted ovarian tissue regained ovarian function as confirmed by return of menses, follicles on ultrasonography and normalized hormone levels.
  • Two embryos were created from the crypreserved tissue after IVF.
  • CONCLUSIONS: Treatment with bone-marrow transplantation and/or high doses of alkylating agents led to ovarian failure in all patients.
  • Autotransplantation of ovarian tissue led to return of ovarian function.
  • [MeSH-major] Cryopreservation. Ovarian Neoplasms / drug therapy. Ovary / drug effects. Ovary / physiology. Ovary / transplantation
  • [MeSH-minor] Adolescent. Adult. Alkylating Agents / pharmacology. Bone Marrow Transplantation. Brain Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Female. Fertility. Follicle Stimulating Hormone / metabolism. Follow-Up Studies. Hodgkin Disease / drug therapy. Humans. Leukemia / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Menstruation. Oocytes / metabolism. Ovarian Follicle / pathology. Ovarian Follicle / ultrasonography. Primary Ovarian Insufficiency. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113042.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


22. Bolaman Z, Kadikoylu G, Kafkas S, Kacar F: Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. Leuk Lymphoma; 2004 Jun;45(6):1285-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcomas are extramedullary tumors (EMD) of malignant myeloid precursor cells.
  • EMD or granulocytic sarcoma of ovary is rare disease.
  • An inguinal mass (diameter 9.5 x 7.6) cm was detected on computed tomography.
  • The histopathological diagnosis of this was obtained from laporascopy was composed of ovotestis and there was marked blastic infiltration in this ovotestis which had myeloid markers on flow cytometry.
  • No response was achieved with combination chemotherapy and the patient died from progressive leukemia.


23. Juretzka MM, Abu-Rustum NR, Sonoda Y, Downey RJ, Flores RM, Park BJ, Hensley ML, Barakat RR, Chi DS: The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol; 2007 Mar;104(3):670-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other eleven patients received primary chemotherapy after undergoing diagnostic laparoscopy alone (4/11) or no further abdominal exploration (7/11).
  • Nine of these patients proceeded to interval cytoreduction, while 2 had pathology demonstrating upper gastrointestinal and lymphoma primaries at the time of VATS.
  • Final diagnosis of primary site of disease included: ovary, 14 (61%); endometrial, 2 (9%); dual ovarian/endometrial primaries, 1 (4%); fallopian tube, 1 (4%); primary peritoneal, 1 (4%); other, 4 (17%).
  • Use of VATS allows for assessment of intrathoracic disease and may help identify candidates for primary cytoreductive surgery and possible intrathoracic cytoreduction versus neoadjuvant chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / surgery. Pleural Effusion, Malignant / surgery. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150248.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Chi DS, Abu-Rustum NR, Sonoda Y, Chen SW, Flores RM, Downey R, Aghajanian C, Barakat RR: The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol; 2004 Aug;94(2):307-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After VATS, all patients had a chest tube placed through the incision, and those with malignant effusions underwent talc pleurodesis either intraoperatively or postoperatively.
  • Median operative time for VATS was 31 min (range: 20-49 min) with no complications attributable to the procedure.
  • Of the six cases with no grossly visible pleural tumor, the pleural fluid was positive for malignant cells in two patients (17%) and negative in four patients (33%).
  • Final diagnosis of primary disease site was as follows: ovary, 9 (75%); fallopian tube, 1 (8%); endometrium, 1 (8%); and lymphoma, 1 (8%).
  • Based on the findings during VATS, laparotomy and attempted cytoreduction were avoided in four patients (33%), and the cytoreductive procedure was modified in one patient (8%).
  • VATS should be considered in these cases to delineate the extent of disease, treat the effusion, and to potentially select patients for either intrathoracic cytoreduction or a neoadjuvant chemotherapy approach.
  • [MeSH-major] Ovarian Neoplasms / surgery. Pleural Effusion, Malignant / surgery. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297166.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Till H, Muensterer O, Graubner U: Laparoscopic adnexectomy of a persistent ovarian tumor in a girl with acute lymphoblastic leukemia relapse. Pediatr Hematol Oncol; 2003 Jul-Aug;20(5):417-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report about a 4-year-old girl who developed a late bone marrow and cutaneous relapse of her pre-B-cell ALL and revealed an enlargement of her left ovary (4 x 3 x 2 cm).
  • Chemotherapy (ALL-REZ-BFM pilot-protocol 2002) achieved effective remission, but the ovarian mass depicted no regression.
  • The authors conclude that in children with ALL relapse and an ovarian tumor, malignant infiltration as well as local response to chemotherapy can be judged only by surgical excision and histopathologic examination.
  • [MeSH-major] Adnexa Uteri / surgery. Gynecologic Surgical Procedures / methods. Laparoscopy. Ovarian Neoplasms / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Bone Marrow Neoplasms / pathology. Child, Preschool. Female. Humans. Ovariectomy / methods. Recurrence. Skin Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12775541.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Ulrich U, Richter O, Wardelmann E, Valter M, Schmutzler R, Sillem M, Possover M, Mallmann P: [Endometriosis and malignoma]. Zentralbl Gynakol; 2003 Jul-Aug;125(7-8):239-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors arising from endometriosis are rare.
  • A frequency of about 1% has been reported with in 80% the ovary, and in 20% extragonadal sites being affected.
  • For extragonadal malignant tumors arising from endometriosis, complete resection followed by post-operative radiotherapy, possibly plus adjuvant progestin therapy, is the treatment of choice.
  • While their treatment follows that of common ovarian cancer, a poorer response to chemotherapy must be considered.
  • As unopposed estrogen replacement therapy has been identified as a risk factor for the development of endometriosis-associated cancer, it is not recommended for hormone replacement therapy in women with a history of endometriosis.
  • Endometriosis and its malignant transformation, perhaps, may serve as a suitable model in this regard.
  • According to recent studies, endometriosis is associated with an increased relative risk of non-Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14505256.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 32
  •  go-up   go-down


27. Oduncu FS, Kimmig R, Hepp H, Emmerich B: Cancer in pregnancy: maternal-fetal conflict. J Cancer Res Clin Oncol; 2003 Mar;129(3):133-46
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common malignancies associated with pregnancy include malignant melanoma, malignant lymphomas and leukemia, and cancer of the cervix, breast, ovary, colon and thyroid.
  • Since it is impossible for prospective randomized clinical trials to be conducted in this field, relevant data have been generated from case reports and matched historical cohort studies in order to evaluate the treatment outcomes and the issues complicating the management of malignancy in the pregnant patient.
  • There is almost always a conflict between optimal maternal therapy and fetal well-being.
  • The maternal interest is for an immediate treatment of the recently diagnosed tumor.
  • However, the optimal therapy, be it chemotherapy, radiotherapy or surgery, may impose great risks on the fetus.
  • We review the available data informing the incidence and impact of the most common malignancies during pregnancy and their treatment on both the pregnant woman and her fetus.
  • The optimal therapy for the tragic diagnosis of cancer in pregnancy requires a collaborative and interdisciplinary approach between gynecologists, oncologists, obstetricians, surgeons, neonatologists, psychologists, nursing staff and other disciplines.
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Embryonic and Fetal Development. Female. Humans. Lymphoma / pathology. Lymphoma / therapy. Maternal-Fetal Relations. Melanoma / pathology. Melanoma / therapy. Pregnancy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1985 Sep;66(3):442-6 [4022506.001]
  • [Cites] N Engl J Med. 1983 Feb 24;308(8):424-31 [6337330.001]
  • [Cites] Blut. 1990 Nov;61(5):298-302 [2271776.001]
  • [Cites] Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1380-1 [8178873.001]
  • [Cites] Am J Hematol. 1991 Nov;38(3):235-7 [1951325.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):304-10 [8674008.001]
  • [Cites] J Am Acad Dermatol. 1993 Oct;29(4):619-30 [8408797.001]
  • [Cites] Bull Cancer. 1979;66(2):165-70 [465749.001]
  • [Cites] Am J Hematol. 1992 Jul;40(3):238-9 [1609781.001]
  • [Cites] Obstet Gynecol Clin North Am. 1993 Mar;20(1):153-63 [8332307.001]
  • [Cites] Obstet Gynecol. 1997 May;89(5 Pt 2):826-8 [9166337.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):445-55 [2678493.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):337-46 [2678485.001]
  • [Cites] Obstet Gynecol. 1995 Jun;85(6):1022-6 [7770248.001]
  • [Cites] Theor Med Bioeth. 1999 Aug;20(4):347-59 [10548930.001]
  • [Cites] Ann Surg. 1943 Nov;118(5):859-70 [17858315.001]
  • [Cites] Ann Surg. 1977 Jul;186(1):1-12 [327949.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):526-30 [9299271.001]
  • [Cites] Am J Obstet Gynecol. 1991 Sep;165(3):565-6 [1892181.001]
  • [Cites] South Med J. 1987 Aug;80(8):984-6 [3616728.001]
  • [Cites] N Engl J Med. 1979 Jul 5;301(1):47 [449911.001]
  • [Cites] Br J Cancer. 1992 Jan;65(1):114-7 [1733434.001]
  • [Cites] Am J Epidemiol. 1993 Oct 1;138(7):482-91 [8213752.001]
  • [Cites] Obstet Gynecol Surv. 1996 Feb;51(2):125-34 [8622836.001]
  • [Cites] Clin Obstet Gynecol. 1975 Jun;18(2):219-25 [1170053.001]
  • [Cites] Ann Intern Med. 1994 Jun 15;120(12):1048-9 [7910438.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):827-31 [6573527.001]
  • [Cites] Br J Cancer. 1977 Dec;36(6):804-9 [597478.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):900-2 [2067030.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]
  • [Cites] Obstet Gynecol Surv. 1984 Nov;39(11):663-78 [6390276.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):855-61 [10071276.001]
  • [Cites] Am J Clin Oncol. 1988 Apr;11(2):159-65 [3162787.001]
  • [Cites] Acta Oncol. 1993;32(4):371-8 [8369123.001]
  • [Cites] Obstet Gynecol. 1969 Dec;34(6):825-9 [5366026.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1704-9 [2224119.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):417-24 [2678490.001]
  • [Cites] Arch Surg. 1989 Oct;124(10):1227-30; discussion 1230-1 [2802988.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):369-76 [2678487.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):78-80 [2026364.001]
  • [Cites] Obstet Gynecol Surv. 1958 Feb;13(1):1-21 [13504622.001]
  • [Cites] Eur J Nucl Med. 1993 Mar;20(3):192-4 [8462605.001]
  • [Cites] Obstet Gynecol. 1977 Aug;50(2):244-52 [876566.001]
  • [Cites] Ann N Y Acad Sci. 1954 Dec 6;60(2):322-58 [14350538.001]
  • [Cites] Int J Cancer. 1997 Jan 17;70(2):155-8 [9009153.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):388-96 [2678488.001]
  • [Cites] Theor Med. 1990 Mar;11(1):51-9 [2339334.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):229-35 [6469398.001]
  • [Cites] J Am Acad Dermatol. 1982 Jun;6(6):977-98 [7047596.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):3-6 [3340063.001]
  • [Cites] Gynecol Oncol. 1984 Jun;18(2):181-205 [6735262.001]
  • [Cites] Am J Med. 1980 Dec;69(6):828-32 [7446548.001]
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):294-8 [8946861.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):518-27 [8004627.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):326-31 [2722058.001]
  • [Cites] J Surg Oncol. 1982 Nov;21(3):179-82 [7132370.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):673-80 [6498065.001]
  • [Cites] Hautarzt. 1993 Jun;44(6):347-52 [8335457.001]
  • [Cites] Clin Lymphoma. 2001 Dec;2(3):173-7 [11779294.001]
  • [Cites] BMJ. 1994 May 28;308(6941):1385-6 [8019246.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):61-4 [8289456.001]
  • [Cites] Obstet Gynecol Surv. 1990 Aug;45(8):509-14 [2198503.001]
  • [Cites] Clin Obstet Gynecol. 1974 Dec;17(4):185-94 [4615858.001]
  • [Cites] Laryngoscope. 1995 Mar;105(3 Pt 1):251-5 [7533229.001]
  • [Cites] J Reprod Med. 1988 Jul;33(7):661-3 [3172066.001]
  • [Cites] Am J Obstet Gynecol. 1952 Mar;63(3):570-8 [14902970.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]
  • [Cites] Arch Intern Med. 1976 Mar;136(3):305-13 [1062970.001]
  • [Cites] J Reprod Med. 1993 Nov;38(11):907-10 [8277492.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):347-68 [2678486.001]
  • [Cites] Obstet Gynecol. 1973 Feb;41(2):211-4 [4684204.001]
  • [Cites] Bioethics. 1989 Oct;3(4):333-41 [11651957.001]
  • [Cites] Theor Med Bioeth. 1999 Jun;20(3):299-308 [11645170.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):861-4 [2835718.001]
  • [Cites] Br J Haematol. 1992 Jun;81(2):167-9 [1643013.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Jul;76(6):583-9 [9246968.001]
  • [Cites] Semin Oncol. 1989 Oct;16(5):397-409 [2678489.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2058-64 [3046546.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1340-4 [3971302.001]
  • [Cites] J Med Soc N J. 1983 Jul;80(7):525-6 [6577200.001]
  • [Cites] Anesthesiology. 1979 Nov;51(5):439-51 [40462.001]
  • [Cites] Am J Obstet Gynecol. 1980 Dec 15;138(8):1165-7 [7446625.001]
  • [Cites] Harefuah. 1990 Sep;119(5-6):146-8 [2227691.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1971 Nov;11(4):208-20 [4332540.001]
  • [Cites] Am J Obstet Gynecol. 1994 Mar;170(3):869-73 [8141218.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):210-1 [3799754.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):876-83 [7662565.001]
  • [Cites] Ann Surg. 1990 May;211(5):552-7; discussion 558-9 [2339917.001]
  • [Cites] Semin Surg Oncol. 1996 Sep-Oct;12(5):370-5 [8873326.001]
  • [Cites] J Clin Oncol. 1987 Jul;5(7):1098-106 [3474357.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):734-6 [8970595.001]
  • [Cites] Lancet. 1978 May 20;1(8073):1083-7 [77377.001]
  • [Cites] World J Surg. 1979 Jul 30;3(3):255-70 [473779.001]
  • [Cites] Nouv Rev Fr Hematol. 1994 Oct;36(5):387-8 [7892134.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):162-5 [9367700.001]
  • [Cites] Obstet Gynecol. 1982 Jun;59(6):735-46 [7078912.001]
  • [Cites] Am J Obstet Gynecol. 1953 Oct;66(4):866-70 [13092169.001]
  • [Cites] Radiology. 1990 Sep;176(3):709-13 [2389030.001]
  • [Cites] Arch Surg. 1986 Nov;121(11):1287-90 [3778201.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):207-10 [7590474.001]
  • (PMID = 12684890.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Germany
  •  go-up   go-down


28. Swiersz LM: Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci; 2002 Mar;955:281-92; discussion 293-5, 396-406
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of these similarities, endometriosis is not considered a malignant disorder.
  • Mutations in the genes that encode for metabolic and detoxification enzymes, such as GALT and GSTM, have been implicated in the pathogenesis of endometriosis and in the progression to carcinoma of the ovary.
  • PTEN, a tumor suppressor commonly mutated (50%) in endometrial carcinoma, is found mutated in endometrioid carcinoma of the ovary, but not in other forms of ovarian cancer.
  • In addition to cancerous transformation at the site of endometriosis, there is recent evidence to indicate that having endometriosis itself may increase a woman's risk of developing non-Hodgkin's lymphoma, malignant melanoma, and breast cancer.
  • [MeSH-major] Breast Neoplasms / etiology. Endometriosis / complications. Melanoma / drug therapy. Ovarian Neoplasms / etiology


29. Han SX, Ma JL, Lv Y, Huang C, Liang HH, Duan KM: Secretory Transactivating Transcription-apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells. World J Gastroenterol; 2008 Jun 21;14(23):3642-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, we designed a secretory protein by adding a secretory signal peptide (SP) to the N terminus of Transactivating Transcription (TAT)-apoptin (SP-TAT-apoptin), to test the hypothesis that it gains an additive bystander effect as an anti-cancer therapy.
  • SP-TAT-apoptin did not, however, cause any cell death in non-malignant human umbilical vein endothelial cells (HUVECs).
  • Most importantly, the conditioned medium from Chinese hamster ovary (CHO) cells transfected with SP-TAT-apoptin also induced significant cell death in HepG2 cells, but not in HUVECs.
  • CONCLUSION: The data demonstrated that SP-TAT-apoptin induces apoptosis only in malignant cells, and its secretory property might greatly increase its potency once it is delivered in vivo for cancer therapy.
  • [MeSH-minor] Animals. CHO Cells. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cricetinae. Cricetulus. Culture Media, Conditioned / metabolism. Endothelial Cells / metabolism. Genetic Therapy / methods. Humans. Recombinant Fusion Proteins / metabolism. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Gene Ther. 2007 Jan;14(1):66-73 [16874360.001]
  • [Cites] Mol Ther. 2006 Nov;14(5):637-46 [16887394.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):391-5 [17223075.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1557-66 [16924230.001]
  • [Cites] Cell Prolif. 2007 Dec;40(6):835-48 [18021174.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:143-69 [17848136.001]
  • [Cites] Apoptosis. 2008 Mar;13(3):437-47 [18188704.001]
  • [Cites] Biochem Pharmacol. 2008 Mar 15;75(6):1348-57 [18164693.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Mar;294(3):C842-55 [18184874.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3060-5 [18059340.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 21;294(4):835-42 [12061783.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27729-36 [12754198.001]
  • [Cites] Biophys J. 2004 Jan;86(1 Pt 1):254-63 [14695267.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):38-42 [14735465.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1957-62 [14738150.001]
  • [Cites] Vet Microbiol. 2004 Feb 4;98(2):89-94 [14741120.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1153-65 [14691460.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1252-8 [15026809.001]
  • [Cites] Hum Cell. 1995 Dec;8(4):189-94 [8721090.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2004 Dec;36(12):817-23 [15592649.001]
  • [Cites] Virus Genes. 2005 Aug;31(1):49-55 [15965608.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7059-64 [16103052.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):10-9 [16410718.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2213-22 [16288204.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii115-23 [16760273.001]
  • [Cites] Drug Resist Updat. 2006 Feb-Apr;9(1-2):40-50 [16621677.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2007 Feb;100(2):127-31 [17244262.001]
  • (PMID = 18595131.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / Culture Media, Conditioned; 0 / Gene Products, tat; 0 / Protein Sorting Signals; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC2719227
  •  go-up   go-down






Advertisement